# Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

> **NCT07414134** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3598 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL

## Key facts

- **NCT ID:** NCT07414134
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-31
- **Primary completion:** 2025-11-28
- **Final completion:** 2025-11-28
- **Target enrollment:** 3598 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07414134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07414134, "Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07414134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*